Use of antisecretory drugs among consumers of non-steroidal anti-inflammatory drugs in the general population

E. Rey, C. Morena Elola-Olaso, F. Rodríguez-Artalejo, G. R. Locke, M. Diaz-Rubio

Research output: Contribution to journalArticle

6 Scopus citations


Background: Overall success of prophylactic strategies against non-steroidal anti-inflammatory drug (NSAID) complications depends on the use of gastroprotective drugs. Aim: We examined the use of antisecretory drugs in NSAID users in the general population of Spain. Participants and Methods: In 2002, a phone interview was conducted with 2500 persons representative of the general population of Spain. Using a validated questionnaire, we asked about the use of NSAID, aspirin and antisecretory drugs, and history of digestive diseases. We estimated the use of antisecretory drugs in NSAID users, according to risk factors for gastrointestinal (GI) lesions associated with NSAID. Results: In total, 425 persons [17.0% (95% CI 15.5-18.5%)] were NSAID users. Of them, 69 persons (16.2%; 95% CI 12.7-19.7%) used antisecretory drugs [proton pump inhibitor (PPI) 11.8% and H2-blocker 4.9%]. Forty-four of the 224 NSAID users (19.6%) with one risk factor for GI lesions were antisecretory drug users (PPI 16%; H2-blocker 4%), compared with 24 of the 197 NSAID users (12.7%) without risk factors (PPI 6.6%; H2-blocker 6.1%). NSAID users with risk factors for GI lesions but without upper GI (UGI) symptoms did not consume more antisecretory drugs than equivalent non-NSAID users (12.9% vs. 10.7%). Conclusion: Current strategies to prevent GI lesions in NSAID users are not effective from a population perspective, especially in subjects without UGI symptoms.

Original languageEnglish (US)
Pages (from-to)1585-1592
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Issue number11-12
StatePublished - Dec 1 2006


ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this